As chimeric antigen receptor (CAR) T-cell therapies are patient-specific, this novel treatment type poses unique challenges. From the British Oncology Pharmacy Association (BOPA) Annual Symposium 2018, held in Birmingham, UK, Anne Black, BPharm, of the Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK, outlines the importance of the role pharmacists can play in ensuring governance and patient safety.
Content on www.vjoncology.com from BOPA 2018 is supported by Napp Pharmaceuticals Ltd
The role of the pharmacist in ensuring safety of CAR T-cell therapy
